- Home
- ATAI vs ATXS Comparison
ATAI vs ATXS Comparison
Compare ATAI & ATXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATAI
- ATXS
- Stock Information
- Founded
- ATAI 2018
- ATXS 2008
- Country
- ATAI Germany
- ATXS United States
- Employees
- ATAI N/A
- ATXS N/A
- Industry
- ATAI Biotechnology: Pharmaceutical Preparations
- ATXS Biotechnology: Pharmaceutical Preparations
- Sector
- ATAI Health Care
- ATXS Health Care
- Exchange
- ATAI Nasdaq
- ATXS Nasdaq
- Market Cap
- ATAI 444.7M
- ATXS 424.4M
- IPO Year
- ATAI 2021
- ATXS 2015
- Fundamental
- Price
- ATAI $4.66
- ATXS $7.67
- Analyst Decision
- ATAI Strong Buy
- ATXS Buy
- Analyst Count
- ATAI 3
- ATXS 6
- Target Price
- ATAI $13.33
- ATXS $32.00
- AVG Volume (30 Days)
- ATAI 5.2M
- ATXS 318.8K
- Earning Date
- ATAI 08-14-2025
- ATXS 08-12-2025
- Dividend Yield
- ATAI N/A
- ATXS N/A
- EPS Growth
- ATAI N/A
- ATXS N/A
- EPS
- ATAI N/A
- ATXS N/A
- Revenue
- ATAI $2,309,000.00
- ATXS N/A
- Revenue This Year
- ATAI $661.36
- ATXS N/A
- Revenue Next Year
- ATAI N/A
- ATXS N/A
- P/E Ratio
- ATAI N/A
- ATXS N/A
- Revenue Growth
- ATAI 510.85
- ATXS N/A
- 52 Week Low
- ATAI $1.03
- ATXS $3.56
- 52 Week High
- ATAI $5.34
- ATXS $12.92
- Technical
- Relative Strength Index (RSI)
- ATAI 58.92
- ATXS 65.14
- Support Level
- ATAI $4.50
- ATXS $7.12
- Resistance Level
- ATAI $4.99
- ATXS $7.91
- Average True Range (ATR)
- ATAI 0.35
- ATXS 0.44
- MACD
- ATAI -0.04
- ATXS 0.11
- Stochastic Oscillator
- ATAI 35.87
- ATXS 90.51
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.
About ATXS Astria Therapeutics Inc.
Astria Therapeutics Inc is a biopharmaceutical company engaged to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Its program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in preclinical development for the treatment of hereditary angioedema. Their second product candidate is STAR-0310, a monoclonal antibody OX40 antagonist that is in preclinical development for the treatment of atopic dermatitis, or AD, an immune disorder associated with loss of skin barrier function and itching.